TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02887040

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atengenal
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astugenal
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
Study: NCT04809558

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue resistance exercise
Description: Participant will complete tongue resistance exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue resistance exercise
Description: Participant will complete tongue resistance exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue resistance exercise
Description: Participant will complete tongue resistance exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue resistance exercise
Description: Participant will complete tongue resistance exercises.
Study: NCT06159881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Cross Linking
Description: Total fluence adapted to thinnest point pachymetry
Study: NCT06076161

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spirulina supplementation and calorie restriction in obese men
Description: The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation and calorie restriction in obese men
Description: The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
Study: NCT05235074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: OH2: Oncolytic Type 2 Herpes Simplex Virus
Study: NCT06012500

Intervention type: DRUG
Intervention: Xenon-129
Description: Inhaled contrast for MRI

Intervention type: DRUG
Intervention: Xenon-129
Description: Inhaled contrast for MRI
Study: NCT06444555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BEP supplement
Description: The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Micronutrient supplement
Description: The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
Study: NCT06556368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarcocimab tedromer
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabirafusp tedromer
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT06432192

Intervention type: DIAGNOSTIC_TEST
Intervention: APO-Easy
Description: Testing for the APOE genotype using the APO-Easy Genotyping test
Study: NCT05787093

Intervention type: DEVICE
Intervention: transabdominal rectal ultrasound
Description: transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol

Intervention type: DEVICE
Intervention: transabdominal rectal ultrasound
Description: transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
Study: NCT03294174

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Ropivacaine administered to provide nerve block

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Ropivacaine administered to provide nerve block

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Ropivacaine administered to provide nerve block
Study: NCT05791409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
Study: NCT05906758

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Angiography
Description: Coronary angiography with less than 20cc of contrast materials

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Coronary angiography with less than 20cc of contrast materials
Study: NCT04859985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR
Description: Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).

Intervention type: DEVICE
Group type: OTHER
Intervention: DES
Description: For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
Study: NCT05247970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-309309
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-309309
Description: Capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule to S-309309 administered orally
Study: NCT06075017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant placement
Description: Comparing the amount and type of biofilm on zirconia vs. titanium implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: Comparing the amount and type of biofilm on zirconia vs. titanium implants
Study: NCT05671445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection
Study: NCT05279066

Intervention type: DEVICE
Intervention: Biostrap Wristband
Description: The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
Study: NCT05047952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician.
Study: NCT05322304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond
Description: Intervention (almond supplementation) and Isocaloric diets (control)
Study: NCT06157814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOMA Care web-based application
Description: The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients and caregivers NOT given access to the web-based application.
Study: NCT04337749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorhexidine scrub
Description: Chorhexidine scrub was given to patients for 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZnO-NPs socks
Description: ZnO-NPs socks were given to patients for 2 weeks

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of chorhexidine scrub and ZnO-NPs socks
Description: Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo socks
Description: Placebo socks were given to patients for 2 weeks
Study: NCT04822064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine and ketamine
Description: Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral chloral hydrate
Description: Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
Study: NCT04758949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101
Description: 200 mg administered intravenously every 2 weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101
Description: 200 mg administered intravenously every 2 weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg administered intravenously every 2 weeks prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 240 mg administered intravenously every 2 weeks prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 200 mg administered intravenously every 2 weeks prior to surgery.
Study: NCT05224986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Schedule
Description: Participants will be asked to maintain a fixed schedule for 12 weeks.
Study: NCT05047952

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be taken once daily.
Study: NCT04730778

Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinine and estimated glomerular filtration rate, on daily basis
Description: Assess establishing criteria of CIN through a week after primary PCI

Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinine and estimated glomerular filtration rate, on daily basis
Description: Assess establishing criteria of CIN through a week after primary PCI
Study: NCT06181266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZH9
Description: ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.
Study: NCT06193720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arnica montana
Description: Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
Study: NCT06181266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZH9
Description: ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZH9
Description: ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.
Study: NCT06193720

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo drug after surgeries
Study: NCT05864521

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Beetroot Juice Supplement (aBRJ)
Description: aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Beetroot Juice Supplement (aBRJ)
Description: aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Beetroot Juice Supplement (pBRJ)
Description: pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Beetroot Juice Supplement (pBRJ)
Description: pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
Study: NCT05824923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial denervation
Description: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) for heart failure
Description: GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) for heart failure
Description: GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion.
Study: NCT06395948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG777
Description: APG777 subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG777
Description: APG777 subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG777
Description: APG777 subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG777
Description: APG777 subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo subcutaneous injection
Study: NCT05028972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Amplifier
Description: The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED

Intervention type: OTHER
Group type: OTHER
Intervention: No Personal Amplifier
Description: The control group will not receive personal amplifiers while they receive care in the ED
Study: NCT05647343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Oral
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Oral
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Oral
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Oral
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Oral
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
Study: NCT05073991

Intervention type: PROCEDURE
Intervention: Lung surgery
Description: Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.

Intervention type: PROCEDURE
Intervention: Open aortic surgery
Description: Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.

Intervention type: PROCEDURE
Intervention: TEVAR
Description: Patients underwent TEVAR.

Intervention type: PROCEDURE
Intervention: EVAR
Description: Patients underwent EVAR.
Study: NCT06477458

Intervention type: OTHER
Intervention: Single inspiratory phase computed tomography.
Description: Utilizing deep learning technology in conjunction with single inspiratory phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.

Intervention type: OTHER
Intervention: Respiratory dual-phase computed tomography.
Description: Utilizing deep learning technology in conjunction with respiratory dual-phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
Study: NCT05647343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
Study: NCT01054287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial falls prevention program
Study: NCT05647343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
Study: NCT05516602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Peer-led support groups over the weekend will include the following activities:~* Peer leader counselling on oral PrEP and HIV risk reduction~* Peer leader discussion to dispel myths and misconceptions around oral PrEP~* Peer leader sharing of experiences of daily pill taking~* Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~* 1-2 role plays per support group session.